Safety and reactogenicity of the BNT162b2 COVID-19 vaccine: Development, post-marketing surveillance, and real-world data

• Hauptverfasser: Frank van den Ouweland (Verfasst von), Nicola Charpentier (Verfasst von), Özlem Türeci (Verfasst von), Ruben Rizzi (Verfasst von), Federico J. Mensa (Verfasst von), Claudia Lindemann (Verfasst von), Shanti Pather (Verfasst von)
• Format: Buch
• Veröffentlicht: Taylor & Francis Group, 2024-12-01T00:00:00Z.
• Schlagworte: article
• Online-Zugang: Connect to this object online.

ABSTRACTThe pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) led to urgent actions by innovators, vaccine developers, regulators, and other stakeholders to ensure public access to protective vaccines while maintaining regulatory agency standards. Although development t...